Grocer banner

GlaxoSmithKline (GSK)

Share Price:
Down 1,650.00p
Change Today:
Market Cap:

GlaxoSmithKline HIV treatment gets European Commission marketing approval

03 Jul 19

LONDON (ShareCast) - (Sharecast News) - GlaxoSmithKline's investee company, ViiV Healthcare, has received European Commission marketing authorisation for Dovato, which treats HIV-1 in adults and adolescents.
Dovato is a two-drug regimen of dolutegravir and lamivudine contained in a single, once-daily pill that would represent a simplification of standard European treatment of HIV.

Deborah Waterhouse, chief executive of ViiV, said: "For many years, the standard of care for treatment-nave people living with HIV in Europe has been a three-drug regimen. The data from our dolutegravir-based two-drug regimen development programme challenges this, and with the authorisation of Dovato, people living with HIV can for the first time start treatment on a once-daily, single-pill, two-drug regimen with the knowledge that efficacy is non-inferior to a three-drug regimen whilst containing fewer antiretrovirals."

The authorisation was won on the basis of studies involving more than 1,400 adults with HIV-1, which demonstrated that the drug was no less effective than the standard three-drug regimen.

Dovato was authorised by the US Food and Drug Administration in April, and further regulatory applications have been submitted worldwide.

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline, its majority owner, and Pfizer, with the venture dedicated to advancing treatment and care for people with HIV.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.


Market Data

Currency UK Pounds
Price 1,650.00p
Change Today -28.00p
52 Week High 1,846.00p
52 Week Low 1,497.40p
Volume 5,873,335
Shares Issued 4,990.55m
Market Cap 82,344m


  Latest Previous
  Q4 Q3
Ex-Div 20-Feb-20 14-Nov-19
Paid 09-Apr-20 09-Jan-20
Amount 23.00p 19.00p